BR0311539A - Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system - Google Patents
Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") systemInfo
- Publication number
- BR0311539A BR0311539A BR0311539-9A BR0311539A BR0311539A BR 0311539 A BR0311539 A BR 0311539A BR 0311539 A BR0311539 A BR 0311539A BR 0311539 A BR0311539 A BR 0311539A
- Authority
- BR
- Brazil
- Prior art keywords
- plg
- glutamate
- dna
- poly
- plasmid dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
"LIBERAçãO AUMENTADA DE UM CONSTRUCTO DE áCIDO NUCLéICO IN VIVO PELO SISTEMA DE POLI-L-GLUTAMATO ('PLG')". DNA plasmídeo liberado por injeção / eletroporação para o músculo do esqueleto pode ser expresso, e níveis fisiológicos de transgene podem ser obtidos na circulação. Não obstante, estabilização de DNA nu pode ser requerida e necessária em alguns casos, como estocagem prolongada em diferentes temperaturas antes de utilização, injeção em um grande número de animais, etc. é imperativo que o composto associado não seja tóxico para as células (por exemplo, células de músculo) ou cause ruptura de DNA plasmídeo. Pode ser preferível para o DNA revestido ter uma tomada similar ou aumentada nas células alvo. Compostos poli-L-glutamato de baixo peso molecular têm todas as propriedades desejadas. Foi determinado que a razão mol / mol de DNA/PLG é a concentração ótima para aplicações terapêuticas de gene para o músculo de esqueleto, resultando em aumentada expressão do transgene, sem dano para o tecido alvo. Além disso, estabilização de DNA plasmídeo por PLG nunca foi observada ou descrita na literatura."INCREASED RELEASE OF IN VIVO NUCLEIC ACID CONSTRUCTION BY THE POLY-L-GLUTAMATE ('PLG') SYSTEM". Plasmid DNA released by injection / electroporation into the skeletal muscle can be expressed, and physiological levels of transgene can be obtained in the circulation. However, bare DNA stabilization may be required and necessary in some cases, such as prolonged storage at different temperatures before use, injection into a large number of animals, etc. It is imperative that the associated compound be non-toxic to cells (e.g., muscle cells) or cause plasmid DNA disruption. It may be preferable for the coated DNA to have a similar or increased uptake in the target cells. Low molecular weight poly-L-glutamate compounds have all the desired properties. It has been determined that the mol / mol ratio of DNA / PLG is the optimal concentration for therapeutic gene applications for skeletal muscle, resulting in increased transgene expression without damage to the target tissue. Moreover, plasmid DNA stabilization by PLG has never been observed or described in the literature.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15667002A | 2002-05-28 | 2002-05-28 | |
| US10/395,709 US20040014645A1 (en) | 2002-05-28 | 2003-03-24 | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| PCT/US2003/016541 WO2003099341A1 (en) | 2002-05-28 | 2003-05-23 | Increased delivery of a nucleic acid constrtuct in vivo by the poly-l-glutamate (plg) system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311539A true BR0311539A (en) | 2005-10-25 |
Family
ID=29586320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311539-9A BR0311539A (en) | 2002-05-28 | 2003-05-23 | Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1513559A4 (en) |
| CN (1) | CN1662261A (en) |
| AU (1) | AU2003273142A1 (en) |
| BR (1) | BR0311539A (en) |
| CA (1) | CA2485976A1 (en) |
| MX (1) | MXPA04011766A (en) |
| WO (1) | WO2003099341A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005089810A1 (en) * | 2004-03-22 | 2008-01-31 | 関西ティー・エル・オー株式会社 | Bone induction method by introducing human bone morphogenetic gene using electroporation method |
| US20060025368A1 (en) * | 2004-07-23 | 2006-02-02 | Advisys, Inc. | Growth hormone releasing hormone enhances vaccination response |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE309358T1 (en) * | 1999-07-26 | 2005-11-15 | Baylor College Medicine | SUPERACTIVE GROWTH HORMONE RELEASING HORMONE ANALOGUES FROM PORK |
| CA2401327C (en) * | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| BR0214869A (en) * | 2001-12-11 | 2005-03-08 | Advisys Inc | Plasmid-mediated supplementation for treatment of chronically ill individuals |
-
2003
- 2003-05-23 BR BR0311539-9A patent/BR0311539A/en not_active Application Discontinuation
- 2003-05-23 CA CA002485976A patent/CA2485976A1/en not_active Abandoned
- 2003-05-23 CN CN 03814625 patent/CN1662261A/en active Pending
- 2003-05-23 EP EP03741818A patent/EP1513559A4/en not_active Withdrawn
- 2003-05-23 AU AU2003273142A patent/AU2003273142A1/en not_active Abandoned
- 2003-05-23 WO PCT/US2003/016541 patent/WO2003099341A1/en not_active Ceased
- 2003-05-23 MX MXPA04011766A patent/MXPA04011766A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099341A1 (en) | 2003-12-04 |
| CN1662261A (en) | 2005-08-31 |
| CA2485976A1 (en) | 2003-12-04 |
| EP1513559A1 (en) | 2005-03-16 |
| AU2003273142A1 (en) | 2003-12-12 |
| EP1513559A4 (en) | 2006-01-18 |
| MXPA04011766A (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061930A1 (en) | MIMETICBODIES OF GLP-1 HUMANS, COMPOSITIONS, METHODS AND USES | |
| ES2607648T3 (en) | Prevention of the synthesis of cellular DNA and poliopédido of inhibition of the cellular proliferation and use of this | |
| BR112013004917A2 (en) | systemic allogeneic stem cell therapies for treating diseases in animals. | |
| MX2009011218A (en) | Nucleic acid microparticles for pulmonary delivery. | |
| Jacobs et al. | Ethyl pyruvate diminishes the inflammatory response to lipopolysaccharide infusion in horses | |
| BR0015419A (en) | Complex containing nucleic acid, pharmaceutical composition, and, methods for controlling a rate of nucleic acid release, and for increasing the function of a nucleic acid, phagocytic cell, and, methods for exhibiting a function of a nucleic acid at a target site, and to treat a disease or disorder | |
| NO20084738L (en) | Compounds and Methods for Modulating the Expression of PCSK9 | |
| Zhou et al. | Comparative analysis of the gut microbial communities of the Eurasian kestrel (Falco tinnunculus) at different developmental stages | |
| BR112015030142A2 (en) | proton binding polymers for oral administration | |
| Di Matteo et al. | Chronic anti-platelet therapy: a contraindication for platelet-rich plasma intra-articular injections? | |
| Grosiak et al. | Age-related changes in the thermoregulatory properties in bank voles from a selection experiment | |
| ES2852225T3 (en) | Nonionic surfactants for the reduction of adipose tissue | |
| BRPI0515553A (en) | stable liquid plasmid DNA formulations | |
| ES2251307B2 (en) | SOLUTION FOR THE UNDEFINED MAINTENANCE OF NUCLEIC ACIDS IN ITS ORIGIN CELL. | |
| BR0311539A (en) | Increased release of a nucleic acid construct in vivo by the poly-l-glutamate ("plg") system | |
| Li et al. | Regulation of spermatozoa motility in response to cations in Russian sturgeon Acipenser gueldenstaedtii | |
| Sharp | The human genome and sport, including epigenetics, gene doping, and athleticogenomics | |
| DE60002603D1 (en) | PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENTS | |
| Gabrić et al. | Comparison between diode laser and conventional technique for soft tissue oral surgery: a pilot study | |
| Wu et al. | Direct adeno-associated viruses injection of murine adipose tissue | |
| ES2573354B1 (en) | Lysenchymal stem cell lysates for the treatment of skeletal muscle lesions | |
| BRPI9914996A (en) | Anabolic implant composition and process to stimulate increased growth rate, greater amount of growth and greater feed efficiency in an animal. | |
| Seifert et al. | Alternate Pathways for Inorganic Phosphate Uptake into Mitochondria | |
| Lubowitz | Editorial commentary: Effects of PRP on cartilage repair using scaffolds are inconclusive | |
| Kim et al. | The predisposing factors of nutritional insufficiency for postoperative patients in surgical ICU |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |